Health

Noam Solomon and Luis Voloch from Immunai

Immunai Raises $215 Million to Accelerate Development of Its Immune-First Drug Actuary Platform

Finance, Health / By

The Series B follows Immunai’s two recent acquisitions and 200% year-over-year growth New York-based biotech Immunai, announced a $215M Series B, increasing the company’s total funding to date to $295M. The new capital will be used to expand Immunai’s “drug …

Immunai Raises $215 Million to Accelerate Development of Its Immune-First Drug Actuary Platform Read More »

Scroll to Top